A deep learning model can identify hospitalized patients at risk for hypoglycemia within 24 hours, according to a study published online June 11 in npj Digital ...

The triple combination regimen nearly doubled median progression free survival to 18.0 months compared with carfilzomib and dexamethasone alone in heavily pretreated patients.

About 31% of pediatric surgery patients receive an opioid prescription at discharge, according to a study published online June 23 in the Journal of the America ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Compared with 2024, the overall rate of 689.2 per 100,000 population was 4.6% lower. HealthDay News — In 2025, the overall US death rate was down 4.6% from 2024, according to a July Vital Statistics ...

Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.

The table below is a review of notable updates that occurred in June 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. BM-3103 ...

Credit: Octapharma. Label expansion establishes the therapy as the first VWF concentrate indicated for routine prophylaxis across all age groups and disease variants. Routine prophylaxis with wilate ...

The share of US adults taking GLP-1 medications to lose weight has reached a record 11%, a new Medicare program that began July 1 could drive that figure higher still.

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein ...